Bevacizumab: Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF

Drugs in R and D

Volumn 3, Issue 1, 2002, Pages 28-30

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; ANGIOGENESIS INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR;

ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; COUGHING; DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DYSPNEA; FEVER; HEADACHE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RASH; THROMBOSIS; BREAST TUMOR; COLORECTAL TUMOR; DRUG ANTAGONISM; FEMALE; REVIEW;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS;

EID: 0036364470     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203010-00006     Document Type: Article

References (6)

1. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor in patients with metastatic cancer. 34th Annual Meeting of the American Society of Clinical Oncology. 17: 210, 16 May 1998. USA. [English]
2. Margolin K, Gordon MS, Talpaz M, Fyfe G, Novotny D, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and longterm safety data. 35th Annual Meeting of the American Society of Clinical Oncology. 18: 435, 15 May 1999. USA. [English]
3. Sledge G, Miller K, Novotny W, Gaudreault J, Ash M, et al. A phase II trial of single-agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth) in patients with relapsed metastatic breast cancer. 36th Annual Meeting of the American Society of Clinical Oncology. 19: 3 (plus oral presentation), 20 May 2000. USA. [English]
4. Borgström P, Hillan KJ, Sriramarao P. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research. 56: 4032-4039, 1 Sep 1996. USA. [English]
5. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Archives of Ophthalmology. 114: 66-71, Jan 1996. USA. [English]
6. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracilleucovorin(FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. 36th Annual Meeting of the American Society of Clinical Oncology. 19: 242, 20 May 2000. USA. [English]